Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Core Insights - Jasper Therapeutics has initiated dosing in its Phase 1b/2a clinical study, ETESIAN, to evaluate briquilimab for allergic asthma, marking a significant milestone in its clinical programs targeting mast cell-driven diseases [1][2] Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company focused on developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) for chronic mast and stem cell diseases, including chronic urticaria and asthma [5] - Briquilimab has shown efficacy and safety in over 160 participants and healthy volunteers, with clinical outcomes in chronic inducible urticaria (CIndU) and as a conditioning agent in various severe conditions [4][5] Clinical Study Details - The ETESIAN study aims to enroll approximately 30 patients across 7 sites in Canada, utilizing a single 180mg subcutaneous dose of briquilimab [2] - Key objectives include demonstrating proof-of-concept in asthma, assessing early and late asthmatic responses, airway hyperresponsiveness, mast cell depletion, and safety [2][4] Mechanism of Action - Briquilimab functions as a targeted aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to c-Kit, leading to mast cell depletion and potentially alleviating inflammatory responses in mast cell-driven diseases [4][5] - The mechanism of mast cell depletion via c-Kit inhibition is considered novel and may address safety issues seen with other c-Kit inhibitors [3]